Studying of anti-inflammatory and antioxidant effects of tectorigenin in ovalbumin-induced asthma mice models

IF 1.9 4区医学 Q3 RESPIRATORY SYSTEM

Clinical Respiratory Journal Pub Date : 2024-04-25 DOI:10.1111/crj.13742

Jingning Guo, Yanping Shi, Yujun Wang, Seyyed Shamsadin Athari, Tao Chen

{"title":"Studying of anti-inflammatory and antioxidant effects of tectorigenin in ovalbumin-induced asthma mice models","authors":"Jingning Guo, Yanping Shi, Yujun Wang, Seyyed Shamsadin Athari, Tao Chen","doi":"10.1111/crj.13742","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Allergic asthma is an important respiratory system problem characterized by airway inflammation, breathlessness, and bronchoconstriction. Allergic asthma and its outcomes are triggered by type 2 allergic immune responses. Tectorigenin is a methoxy-isoflavone with anti-inflammatory effects. In this study, we investigated the effects of tectorigenin on the pathophysiology of allergic asthma in an animal model.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Asthmatic mice were treated with tectorigenin. Then airway hyperresponsiveness (AHR), eosinophil percentage, levels of interleukin (IL)-33, IL-25, IL-13, IL-5, IL-4, total and ovalbumin (OVA)-specific immunoglobulin (Ig)E, and lung histopathology were evaluated.</p>\n </section>\n \n <section>\n \n <h3> Result</h3>\n \n <p>Tectorigenin significantly (P 〈 0.05) reduced eosinophil infiltration (41 ± 7%) in the broncho-alveolar lavage fluid (BALF), serum IL-5 level (41 ± 5, pg/mL), and bronchial and vascular inflammation (scores of 1.3 ± 0.2 and 1.1 ± 0.3, respectively) but had no significant effects on AHR, serum levels of IL-33, −25, −13, and −4 (403 ± 24, 56 ± 7, 154 ± 11, and 89 ± 6 pg/mL, respectively), total and OVA-specific IgE (2684 ± 265 and 264 ± 19 ng/mL, respectively), goblet cell hyperplasia, and mucus production.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Tectorigenin could control inflammation and the secretion of inflammatory mediators of asthma, so it can be regarded as a potential antiasthma treatment with the ability to control eosinophilia-related problems.</p>\n </section>\n </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"18 4","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.13742","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Respiratory Journal","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/crj.13742","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Allergic asthma is an important respiratory system problem characterized by airway inflammation, breathlessness, and bronchoconstriction. Allergic asthma and its outcomes are triggered by type 2 allergic immune responses. Tectorigenin is a methoxy-isoflavone with anti-inflammatory effects. In this study, we investigated the effects of tectorigenin on the pathophysiology of allergic asthma in an animal model.

Methods

Asthmatic mice were treated with tectorigenin. Then airway hyperresponsiveness (AHR), eosinophil percentage, levels of interleukin (IL)-33, IL-25, IL-13, IL-5, IL-4, total and ovalbumin (OVA)-specific immunoglobulin (Ig)E, and lung histopathology were evaluated.

Result

Tectorigenin significantly (P 〈 0.05) reduced eosinophil infiltration (41 ± 7%) in the broncho-alveolar lavage fluid (BALF), serum IL-5 level (41 ± 5, pg/mL), and bronchial and vascular inflammation (scores of 1.3 ± 0.2 and 1.1 ± 0.3, respectively) but had no significant effects on AHR, serum levels of IL-33, −25, −13, and −4 (403 ± 24, 56 ± 7, 154 ± 11, and 89 ± 6 pg/mL, respectively), total and OVA-specific IgE (2684 ± 265 and 264 ± 19 ng/mL, respectively), goblet cell hyperplasia, and mucus production.

Conclusion

Tectorigenin could control inflammation and the secretion of inflammatory mediators of asthma, so it can be regarded as a potential antiasthma treatment with the ability to control eosinophilia-related problems.

Abstract Image

查看原文本刊更多论文

在卵清蛋白诱导的哮喘小鼠模型中研究橘霉素的抗炎和抗氧化作用

背景过敏性哮喘是一种重要的呼吸系统疾病，以气道炎症、呼吸困难和支气管收缩为特征。过敏性哮喘及其后果是由 2 型过敏性免疫反应引发的。Tectorigenin 是一种具有抗炎作用的甲氧基异黄酮。本研究在动物模型中探讨了蓟黄素对过敏性哮喘病理生理学的影响。方法用蓟黄素治疗哮喘小鼠。然后评估气道高反应性（AHR）、嗜酸性粒细胞百分比、白细胞介素（IL）-33、IL-25、IL-13、IL-5、IL-4、总免疫球蛋白（Ig）E和卵清蛋白（OVA）特异性免疫球蛋白（Ig）E的水平以及肺组织病理学。结果 Tectorigenin 能明显（P 〈 0.05）减少支气管肺泡灌洗液（BALF）中的嗜酸性粒细胞浸润（41 ± 7%）、血清 IL-5 水平（41 ± 5，pg/mL）、支气管和血管炎症（评分分别为 1.3 ± 0.2 和 1.1 ± 0.3），但对AHR、血清IL-33、-25、-13和-4水平（分别为403 ± 24、56 ± 7、154 ± 11和89 ± 6 pg/mL）、总IgE和OVA特异性IgE（分别为2684 ± 265和264 ± 19 ng/mL）、小管细胞增生和粘液分泌无显著影响。结论 Tectorigenin 能控制炎症和哮喘炎症介质的分泌，因此可被视为一种潜在的抗哮喘治疗方法，具有控制嗜酸性粒细胞相关问题的能力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Respiratory Journal 医学-呼吸系统

CiteScore

3.70

自引率

0.00%

发文量

104

审稿时长

>12 weeks

期刊介绍： Overview Effective with the 2016 volume, this journal will be published in an online-only format. Aims and Scope The Clinical Respiratory Journal (CRJ) provides a forum for clinical research in all areas of respiratory medicine from clinical lung disease to basic research relevant to the clinic. We publish original research, review articles, case studies, editorials and book reviews in all areas of clinical lung disease including: Asthma Allergy COPD Non-invasive ventilation Sleep related breathing disorders Interstitial lung diseases Lung cancer Clinical genetics Rhinitis Airway and lung infection Epidemiology Pediatrics CRJ provides a fast-track service for selected Phase II and Phase III trial studies. Keywords Clinical Respiratory Journal, respiratory, pulmonary, medicine, clinical, lung disease, Abstracting and Indexing Information Academic Search (EBSCO Publishing) Academic Search Alumni Edition (EBSCO Publishing) Embase (Elsevier) Health & Medical Collection (ProQuest) Health Research Premium Collection (ProQuest) HEED: Health Economic Evaluations Database (Wiley-Blackwell) Hospital Premium Collection (ProQuest) Journal Citation Reports/Science Edition (Clarivate Analytics) MEDLINE/PubMed (NLM) ProQuest Central (ProQuest) Science Citation Index Expanded (Clarivate Analytics) SCOPUS (Elsevier)